Search results
John M. McPherson's 82 research works with 5,669 citations and 7,238 reads, including: Abstract 4094: Neutralizing anti-TGF-β antibodies elicit heterogeneous therapeutic responses in a panel of ...
Aug 27, 2013 · John McPherson is an employee of Sanofi-Genzyme Citation: Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.
- James P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, Jing Sun, Mona Jacobs-Small, Jennifer Hull,...
- 2013
Feb 1, 2007 · He started at Genzyme in 1989 as senior vice president of research, and seven years later was named chief scientific officer. "When I met him, to tell you the truth, I was expecting something a little different," says John McPherson, Genzyme's head of biological products R&D. McPherson first hired Smith at Integrated in 1988.
The National Cancer Institute has a Cooperative Research and Development Agreement with the Genzyme Corporation Conflict of Interest: Scott Lonning and John M. McPherson are employees of the Genzyme Corporation and thus may have the conflict of interest
- Shun Takaku, Masaki Terabe, Elena Ambrosino, Judy Peng, Scott Lonning, John M. McPherson, Jay A. Ber...
- 2010
Aug 10, 2017 · John McPherson, a former Genzyme executive who collaborated with Sporn, is optimistic that one of these drugs will soon make it to market — and hopeful Sporn will see that happen.
- Elie Dolgin
- 2017
John McPherson, a former Genzyme execu - tive who collaborated with Sporn, is optimistic that one of these drugs will soon make it to mar - ket — and hopeful Sporn will see that happen.
Recombinant human protein C was the generous giff of Dr. John McPherson, Genzyme Corp., Framingham, MA, and was purified as described (12). Chromogenic substrate D-valyl-L-leucyl-L-arginine-p-ni- troanilide (S-2266) was from Kabi Vitrum, Franklin, OH. Mouse mono-
